New data confirms rare heart problems after vaccination

Heart problems after the Pfizer/BioNTech and Moderna vaccines were confirmed as rare and rapidly recovering side effects by an independent advisory panel to the US Centers for Disease Control, CDC, at a meeting Monday (30).

Follow Semper Família on Instagram!

In addition to being more common after the second dose of vaccines, the committee, According to the New York Times,, highlighted that the profile of people who had this side effect was, essentially, Teenage boys and young men.

And the rarity, according to the data released, was from 14 to 20 cases of heart problems each million doses (Second application) Administered to persons between the ages of 12 and 39 years.

The benefits outweigh the risks

Even among ‘at-risk’ groups, the benefits of vaccination outweigh the potential cardiac side effects, data released Monday Confirm what the experts have highlighted.

Data released during the meeting by representatives of the Centers for Disease Control and Prevention highlights the numbers for Pfizer’s vaccines. For every million doses given to boys aged 16 to 17, 73 cases of heart problems can be expected. However, the same doses have prevented more than 56,000 cases of Covid-19 and 500 hospitalizations linked to the disease.

Regarding gender differences, men tend to be more at risk than women. Data from the Pfizer vaccine also indicate that for every 1 million doses applied, 71.5 cases of myocarditis were reported in boys aged 16 to 17 years. Among girls of the same age, 8.1 cases were identified.

symptoms

The most specific heart problems were Myocarditis, or myocarditis, and Pericarditis, dermatitis covering the heart, pericardium. The most commonly described symptom is chest pain, which may appear between the third and fifth day after vaccination.

If symptoms develop after a Covid-19 infection and not after vaccinations, more attention is needed. A new study was published in The New England Journal of Medicine, which evaluated the safety of the Pfizer/BioNTech vaccine, highlighted the risk of myocarditis associated with the immunizing agent, but also of the infection itself.

“In this nationwide universal vaccination site study, BNT162b2 vaccine was not associated with an elevated risk for the majority of adverse events examined. The vaccine was associated with an increased risk of developing myocarditis (1 to 5 events per 100,000 people). The risk of This potentially serious adverse event, and many other serious adverse events, have increased dramatically following SARS-CoV-2 infection.” Spotlight on researchers. The article was published on August 25.